Last reviewed · How we verify
GLPG2222
At a glance
| Generic name | GLPG2222 |
|---|---|
| Sponsor | Galapagos NV |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis (PHASE2)
- A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 (PHASE2)
- A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor (PHASE1)
- A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis. (PHASE1)
- A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis (PHASE2)
- A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects. (PHASE1)
- A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis (PHASE2)
- A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLPG2222 CI brief — competitive landscape report
- GLPG2222 updates RSS · CI watch RSS
- Galapagos NV portfolio CI